A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

Phase 1 Active not recruiting 30 enrolled Wugen, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is a Phase 1b open-label study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of WU-NK-101 in combination with cetuximab in patients with advanced and/or metastatic CRC (Cohort 1), and in patients with advanced and/or metastatic SCCHN (Cohort 2). The overall study will be comprised of two phases, a Dose Escalation Phase, and a Cohort Expansion Phase.

Timeline

Start: 2024-05-21
Primary completion: 2025-09-30
Completion: 2026-06-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetuximab	Monoclonal antibody	500 mg/m2	—
Subject	WU-NK-101	Cell therapy	—	—

A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

Summary

Timeline

Drugs

Indications